Vor Bio


Vor Bio

Vor Bio is a cell and genome engineering company with a mission to change the standard of care for patients with blood cancer by engineering hematopoietic stem cells (HSCs) to enable targeted therapies post-transplant. Realizing the potential to create value for patients by combining Vor Bio’s approach with Janssen’s targeted cancer therapies, Johnson & Johnson Innovation first participated in Vor Bio’s Series A financing round through JJDC in 2019, and then, in 2020, facilitated a research collaboration between Vor Bio and Janssen Biotech.

The collaboration is designed to investigate the opportunity to develop a treatment for acute myeloid leukemia (AML) through the combination of Vor Bio’s eHSC transplant platform and one of Janssen’s clinical-stage bi-specific antibodies.

We are thrilled with our collaboration with Janssen, as we continue to explore our platform’s potential to pair with a broad spectrum of targeted therapy modalities for the treatment of patients with blood cancer. We believe this unique combination will leverage each technology’s strengths, while protecting patients against off-target effects of these powerful immunotherapies.

Tirtha Chakraborty, Ph.D.
Chief Scientific Officer, Vor Bio